Skip to main content
Egyptian Journal of Radiology and Nuclear Medicine

Table 2 Treatment response to NAC by CESM

From: Role of contrast-enhanced spectral mammography in the assessment of residual disease following neoadjuvant chemotherapy in patients with breast cancer

 

CESM

n

%

CR

26

18.3

Non-CR

  PR

58

40.8

  SD

54

38.0

  PD

4

2.8

  1. CESM contrast-enhanced spectral mammography, CR complete response, PR partial response, SD stable disease, PD progressive disease, n number
Back to article page